ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Lupus nephritis"

  • Abstract Number: 0035 • ACR Convergence 2020

    Distinct Biological Pathways in Both Blood and Kidney Further Define Molecular Profiles Across Diverse Nephritides

    Loqmane Seridi1, Matteo Cesaroni1, Qingxuan Song2, Ashley Orillion1, Frédéric Baribaud1, Tatiana Ort1, Sheng Gao2, Tomas Parker3, James Chevalier3, Dan Levine3, Alan Perlman3 and Jarrat Jordan1, 1Janssen Research & Development, LLC, Spring House, PA, 2Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, 3The Rogosin Institute, New York Presbyterian Hospital-Weill Medical College of Cornell University New York, NY, USA., New York, NY

    Background/Purpose: Approximately 40% of SLE patients will develop Lupus Nephritis (LN), of which 10-30 % will progress to end-stage renal disease. To further understand LN…
  • Abstract Number: 0855 • ACR Convergence 2020

    Treatment of SLE with or Without Nephritis with the Immunoproteasome Inhibitor KZR-616: Updated Results of the MISSION Study

    Richard Furie1, Samir Parikh2, Kenneth Harvey3, Christopher Kirk4, Darrin Bomba4 and MK Farmer5, 1Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 2The Ohio State University, Columbus, OH, 3Kezar Life Sciences, South San Francisco, CA, 4Kezar Life Sciences, Inc, San Francisco, CA, 5Kezar, Raleigh, NC

    Background/Purpose: Immunoproteasome inhibition has demonstrated meaningful therapeutic potential in preclinical models of systemic lupus erythematosus (SLE) and lupus nephritis (LN). KZR-616 is a first-in-class selective…
  • Abstract Number: 1513 • ACR Convergence 2020

    Role of Platelet C4d in Thrombosis and Lupus Nephritis

    Michelle Petri1, Jessica Li2, John Conklin3, Tyler O'Malley4, Jo-Anne Ligayon5, Leilani Wolover5 and Thierry Dervieux6, 1Johns Hopkins University School of Medicine, Timonium, MD, 2Johns Hopkins University, Baltimore, MD, 3Exagen Inc., Vista, CA, 4Exagen, Inc, San Diego, CA, 5Exagen Diagnostics, San Diego, CA, 6Prometheus Biosciences, Inc. (former employee of Exagen Diagnostics), Irvine, CA

    Background/Purpose: The SLE thrombosis risk equation contains three components:  lupus anticoagulant (dRVVT), low C3 and C4d bound to platelets (platelet C4d).  We examined the role…
  • Abstract Number: 1814 • ACR Convergence 2020

    The Association of Urinary Membrane Attack Complex (C5b-9) with Proteinuria and Glomerular Activity in Lupus Nephritis

    Shudan Wang1, Erica Moore2, Brianna Lally3, Beatrice Goilav4, Chaim Putterman3 and Anna Broder5, 1Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY, 2Albert Einstein College of Medicine, Bronx, 3Albert Einstein College of Medicine, Bronx, NY, 4The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, 5Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

    Background/Purpose: Complement activation is known to play a major role in lupus nephritis (LN). Urinary membrane attack complex (C5b-9) has been shown to correlate with…
  • Abstract Number: 0242 • ACR Convergence 2020

    Autoantibody Profile and Ethnicity: Risk Factors for Accelerated Development of Lupus Nephritis

    Majed Albirdisi1, David d'Cruz2, Shirish Sangle2 and Natasha Jordan3, 1King Fahad Medical City, riyadh, Saudi Arabia, 2guys and st thomas hospital, london, United Kingdom, 3addebrooke's hospital, cambridge, United Kingdom

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease. African ancestry is associated with an increased risk of Lupus Nephritis (LN). Anti-DNA autoantibodies play…
  • Abstract Number: 0859 • ACR Convergence 2020

    Biomarkers of B-cell Depletion and Response in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis

    Ed Vital1, Philippe Remy2, Luis Fernando Quintana Porras3, Laurent Chiche4, Dominique Chauveau5, Richard Furie6, Thomas Schindler7, Jay Garg8, Matthew Cascino8, Zahir Amoura9, Andrea Doria10, Cary Looney8 and Dario Roccatello11, 1University of Leeds; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 2APHP Groupe Hospitalier Henri-Mondor, Creteil, France, 3Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, 4Hôpital Européen, Marseille, France, 5Hôpital Rangueil, Centre Hospitalier Univ de Toulouse, Toulouse, France, 6Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 7F. Hoffmann-La Roche Ltd., Basel, Switzerland, 8Genentech, Inc., South San Francisco, CA, 9Hôpital Pitié-Salpêtrière, Paris, 10University of Padua, Padua, Italy, 11S Giovanni Hospital, Univ of Turin, Turin, Italy

    Background/Purpose: Incomplete B-cell and plasmablast depletion, as measured using highly sensitive flow cytometry (HSFC), is associated with lower response rates following rituximab in SLE [1].…
  • Abstract Number: 1514 • ACR Convergence 2020

    The Impact of Renal Transplantation on Cardiovascular Events Among Patients with End-State Kidney Disease Due to Lupus Nephritis: A Nationwide Cohort Study

    April Jorge1, Xiaoqing Fu2, Yuqing Zhang3, Hyon Choi4 and Zachary Wallace5, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, 3Massachusetts General Hospital, Harvard Medical School, Boston, 4Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, 5Harvard Medical School, Boston

    Background/Purpose:A major complication of systemic lupus erythematosus (SLE) is the progression of lupus nephritis (LN) to end-stage kidney disease (ESKD). Both SLE and ESKD are…
  • Abstract Number: 1815 • ACR Convergence 2020

    Dynamic Changes in Microbiota Representation of a Gut Pathobiont and Clinical Disease Activity in Patients with Lupus Nephritis

    Doua Azzouz1, Ze Chen2, Zhi Li3, Peter Izmirly4, Jing Deng1, David Fenyo3, Jill Buyon1, Alexander Alekseyenko5 and Gregg Silverman6, 1Department of Medicine, NYU School of Medicine, New York, NY, 2Department of Microbiology, NYU School of Medicine, New York, NY, 3Institute for Systems Genetics, NYU School of Medicine, New York, NY, 4Department of Medicine, New York University School of Medicine, New York, NY, 5Medical University of South Carolina, Charleston, SC, 6Laboratory of B cell immunobiology, Department of Medicine, NYU School of Medicine, New York, NY

    Background/Purpose: From a cross-sectional cohort, we have recently identified a candidate human gut pathobiont, Ruminococcus gnavus (RG) of the Lachnospiraceae family and Blautia genus that…
  • Abstract Number: 0243 • ACR Convergence 2020

    The Role of Anti-dsDNA Antibodies in Predicting Incident Lupus Nephritis in Newly Diagnosed Lupus

    Pooja Kumari1, Viswanathan Ramakrishnan2, Jihad Obeid2, Diane Kamen3 and Jim Oates4, 1The university of Tennesse Health Science center, Memphis, TN, 2medical university of south carolina, south carolina, 3Medical University of South Carolina, Charleston, SC, 4Medical University of South Carolina, Charleston, SC, Charleston, SC

    Background/Purpose: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) that leads to significant morbidity and mortality. Therefore, it is essential to…
  • Abstract Number: 0862 • ACR Convergence 2020

    Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE

    Teun van Gelder1, Robert Huizinga2, Neil Solomons2 and Laura Lisk3, 1Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, 2Aurinia Pharmaceuticals, Victoria, BC, Canada, 3Aurinia Pharmaceuticals Inc., Victoria, BC, Canada

    Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor, structurally similar to cyclosporine A (CsA). In a Phase 3 clinical trial in patients with active lupus…
  • Abstract Number: 1515 • ACR Convergence 2020

    Renal Responder Status and Associated Clinical Variables in the Lupus Accelerating Medicines Partnership Cohort

    Philip Carlucci1, Andrea Fava2, Kristina Deonaraine1, Jessica Li3, David Wofsy4, Judith James5, Chaim Putterman6, Betty Diamond7, Derek Fine8, Jose Monroy-Trujillo8, Kristin Haag8, William Apruzzese9, H. Michael Belmont10, Peter Izmirly11, Sean Connery12, Fernanda Payan-Schober12, Richard Furie13, Celine Berthier14, Maria Dall'Era15, Kerry Cho16, Diane Kamen17, Kenneth Kalunian18, The Accelerating Medicines Partnership in SLE Network19, Michelle Petri20 and Jill Buyon21, 1New York University School of Medicine, New York, 2Johns Hopkins, Baltimore, 3Johns Hopkins University, Baltimore, MD, 4University of California San Francisco, San Francisco, CA, 5Oklahoma Medical Research Foundation, Oklahoma City, 6Albert Einstein College of Medicine, Bronx, NY, 7Northwell Health, Hartford, 8Johns Hopkins University, Baltimore, 9., Boston, 10NYU School of Medicine, New York, NY, 11Department of Medicine, New York University School of Medicine, New York, NY, 12Texas Tech University Health Sciences Center, Lubbock, 13Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 14University of Michigan, Ann Arbor, 15Division of Rheumatology, University of California, San Francisco, CA, 16University of California San Francisco, San Francisco, 17Medical University of South Carolina, Charleston, SC, 18School of Health Sciences, University of California, La Jolla, 19Multiple Institutions, Multiple Cities, 20Johns Hopkins University School of Medicine, Baltimore, 21Department of Medicine, NYU School of Medicine, New York, NY

    Background/Purpose: Poor therapeutic response rates contribute to the increased morbidity and mortality associated with lupus nephritis. Early identification of patients likely to respond is crucial…
  • Abstract Number: 1816 • ACR Convergence 2020

    Urine Biomarkers of Tubulointersitital Damage in Lupus Nephritis

    Brianna Lally1, Shudan Wang2, Sammy Chalmers3, Wenzhu Mowrey3, Tamar Rubinstein4, Beatrice Goilav5 and Anna Broder6, 1Albert Einstein College of Medicine, Bronx, NY, 2Albert Einstein College of Medicine, New York, NY, 3Albert Einstein College of Medicine, Bronx, 4Albert Einstein College of Medicine / Montefiore Medical Center, White Plains, NY, 5The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, 6Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

    Background/Purpose: Tubulointerstitial disease (TID), defined as tubulointerstitial inflammation (TII) or interstitial fibrosis/tubular atrophy (IFTA), is associated with progression to end stage renal disease (ESRD) in…
  • Abstract Number: 0250 • ACR Convergence 2020

    Lupus Nephritis and Renal Outcomes in African-Americans: The Accelerating Medicines Partnership Cohort Experience

    Andrea Fava1, Jessica Li1, Philip Carlucci2, David Wofsy3, Judith James4, Chaim Putterman5, Betty Diamond6, Derek Fine7, Jose Monroy-Trujillo7, Kristin Haag7, Kristina Deonaraine8, The Accelerating Medicines Partnership in SLE Network9, William Apruzzese10, Jill Buyon11 and Michelle Petri12, 1Johns Hopkins University, Baltimore, MD, 2New York University School of Medicine, New York, NY, 3University of California San Francisco, San Francisco, CA, 4Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK, 5Albert Einstein College of Medicine, Bronx, NY, 6Northwell Health, Manhasset, NY, 7Johns Hopkins University, Baltimore, 8New York University School of Medicine, New York, 9Multiple Institutions, Multiple Cities, 10., Boston, 11Department of Medicine, NYU School of Medicine, New York, NY, 12Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: The Accelerating Medicines Partnership (AMP) will use multi-omics modalities including single cell RNA sequencing to understand lupus nephritis with the ultimate goal to devise…
  • Abstract Number: 0867 • ACR Convergence 2020

    Hydroxychloroquine Use Predicts Significantly Higher Patient and Graft Survival in Post-Renal Transplant Lupus Nephritis Patients

    Shivani Garg1, Tripti Singh1, Sarah Panzer2 and Christie Bartels3, 1UW Madison, Madison, WI, 2UW-Madison, Madison, 3University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI

    Background/Purpose: Hydroxychloroquine (HCQ) is a pivotal therapy for lupus nephritis (LN) as it contributes to 65% lower mortality and 84% lower renal damage compared to…
  • Abstract Number: 1516 • ACR Convergence 2020

    The Value of Renal Biopsy at Lower Levels of Proteinuria in Patients Enrolled in the Lupus Accelerating Medicines Partnership

    Philip Carlucci1, Kristina Deonaraine1, Andrea Fava2, Jessica Li3, David Wofsy4, Judith James5, Chaim Putterman6, Betty Diamond7, Derek Fine8, Jose Monroy-Trujillo8, Kristin Haag8, William Apruzzese9, H. Michael Belmont10, Peter Izmirly11, Sean Connery12, Fernanda Payan-Schober12, Richard Furie13, Celine Berthier14, Maria Dall'Era15, Kerry Cho16, Diane Kamen17, Kenneth Kalunian18, The Accelerating Medicines Partnership in SLE Network19, Michelle Petri20 and Jill Buyon21, 1New York University School of Medicine, New York, 2Johns Hopkins, Baltimore, 3Johns Hopkins University, Baltimore, MD, 4University of California San Francisco, San Francisco, CA, 5Oklahoma Medical Research Foundation, Oklahoma City, 6Albert Einstein College of Medicine, Bronx, NY, 7Northwell Health, Hartford, 8Johns Hopkins University, Baltimore, 9., Boston, 10NYU School of Medicine, New York, NY, 11Department of Medicine, New York University School of Medicine, New York, NY, 12Texas Tech University Health Sciences Center, Lubbock, 13Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 14University of Michigan, Ann Arbor, 15Division of Rheumatology, University of California, San Francisco, CA, 16University of California San Francisco, San Francisco, 17Medical University of South Carolina, Charleston, SC, 18School of Health Sciences, University of California, La Jolla, 19Multiple Institutions, Multiple Cities, 20Johns Hopkins University School of Medicine, Baltimore, 21Department of Medicine, NYU School of Medicine, New York, NY

    Background/Purpose: Lupus nephritis continues to be the complication with the highest standardized mortality ratio in Systemic Lupus Erythematosus (SLE), and a late diagnosis associates with…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 16
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.